Advicenne
ALDVI | PA
Overview
Corporate Details
- ISIN(s):
- FR0013296746 (+1 more)
- LEI:
- 969500YT5VMEYAYODW34
- Country:
- France
- Address:
- 262 RUE DU FAUBOURG SAINT-HONORE, 75008 PARIS
- Website:
- https://advicenne.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
For more than 10 years, Advicenne has been dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults with rare renal diseases. At Advicenne we are dedicated to improving patients’ daily health and life. Our employees in France and the United States are committed to tackle the challenge of high unmet medical need to improve quality of life for patients and their caregivers. Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) was in 2021 approved by the European Medicine Agency and MHRA.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-16 08:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 114.8 KB | |
| 2025-04-29 18:00 |
Regulatory News Service
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rap…
|
French | 182.1 KB | |
| 2025-04-29 18:00 |
Regulatory News Service
Annual financial and audit reports / Terms of availability of the annual financ…
|
English | 152.3 KB | |
| 2025-03-27 19:12 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 324.3 KB | |
| 2025-03-27 19:12 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 336.8 KB | |
| 2025-01-23 18:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 233.9 KB | |
| 2025-01-23 18:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 243.6 KB | |
| 2024-12-19 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 196.5 KB | |
| 2024-12-19 18:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 163.2 KB | |
| 2024-11-28 18:00 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 192.1 KB | |
| 2024-11-28 18:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 190.8 KB | |
| 2024-10-01 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 216.0 KB | |
| 2024-10-01 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 243.5 KB | |
| 2024-09-18 18:15 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 278.7 KB | |
| 2024-09-18 18:15 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 314.0 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-10-04 | N/A | Other | Other | 1,452,282 | 3,499,999.62 EUR |
| 2023-10-04 | N/A | Other | Buy | 41,493 | 99,998.13 EUR |
| 2023-10-02 | N/A | Other | Other | 414,937 | 999,998.17 EUR |
| 2023-09-21 | N/A | Other | Sell | 22,336 | 22.34 EUR |
| 2023-09-15 | N/A | Other | Sell | 134,492 | 13.45 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Adocia | France | ADOC | |
|
Aelis Farma | France | AELIS | |
|
Aker BioMarine | Norway | AKBM | |
|
ALK-Abelló | Denmark | ALK | |
|
Alligator Bioscience | Sweden | ATORX | |
|
Alvotech Holdings S.A | Luxembourg | ALVO | |
|
AlzeCure Pharma | Sweden | ALZCUR | |
|
Alzinova AB | Sweden | ALZ | |
| Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS | Türkiye | ANGEN | ||
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR |